Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059 29/11/2024

1,660 USD (+5,73%)

(+5,73%) 29/11/2024

Grafiek Evaxion Biotech A/S - ADR

Grafiek Evaxion Biotech A/S - ADR

1 dag1d 5,73%
1 week1w 9,93%
1 maand1m -37,12%
3 maanden3m -47,47%
6 maanden6m -52,84%
1 jaar1j 102,46%
5 jaar5j -83,22%

Evaxion Biotech A/S - ADR in het nieuws

Toon enkel gratis nieuws

2 december 2024 · Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress · Persbericht

13 november 2024 · Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing · Persbericht

12 november 2024 · Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 · Persbericht

31 oktober 2024 · Evaxion announces business update and third quarter 2024 financial results · Persbericht

28 oktober 2024 · Evaxion to announce business update and third quarter 2024 financial results on October 31 · Persbericht

9 oktober 2024 · Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials · Persbericht

3 oktober 2024 · Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform · Persbericht

26 september 2024 · Evaxion significantly expands vaccine development collaboration with MSD · Persbericht

19 september 2024 · Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction · Persbericht

16 september 2024 · Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 · Persbericht

Profiel Evaxion Biotech A/S - ADR

Werknemers: 79

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe